Skip to main content

MDRNA Regains Compliance with Nasdaq's Minimum Bid Requirement


MDRNA announced this week that it has received notification from the Nasdaq Stock Market that its shares have regained compliance with the exchange's $1 minimum bid requirement for continued listing.

"We are pleased to have regained compliance with Nasdaq's Minimum Bid Price Requirement and believe it reflects the great progress we have made in restructuring and re-launching MDRNA as a premier RNAi drug discovery company," MDRNA President and CEO Michael French said in a statement.

MDRNA, however, still has yet to meet the Nasdaq's listing requirement of a minimum of $10 million in stockholders' equity. The company said earlier this month that it presented a plan to regain compliance to the Nasdaq's listing qualifications panel in April and expects to receive the panel's response by the end of the month.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.